ProJect Pharmaceutics was granted a US patent on a novel formulation which effectively stabilizes the anti-cancer drug Bendamustine and other N-mustard cancer drugs like Chlorambucil, Melphalan, Melflufen, etc. in liquid state at room temperature for up to 24 months.
LIQUID PHARMACEUTICAL FORMULATION
US-Patent No: 11,752,135
US-Application No: 17/042,795
Contact us for:
– Details of the formulation and stability data under various conditions
– Technical assistance to ensure further development and GMP manufacturing